Slide 1: Corporate Presentation
Corporate Presentation Aug 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Harrow – A Leading Provider of Ophthalmic Disease Management Solutions in North America
Harrow – A Leading Provider of Ophthalmic Disease Management Solutions in North America Largest U.S. portfolio of ophthalmic Key revenue drivers are best-in- Scalable commercial platform prescription products for the front & class products with large market with an innovative market back of the eye
Slide 4: Investment Highlights
Investment Highlights 2025 Revenue expected to be more than $280 million, including: 1. VEVYE – large market; category-leading potential; 66% Q/o/Q Rx volume growth 2. IHEEZO – 25% growth in unit demand in Q2 2025 vs Q1 2025 3. TRIESENCE – 32% growth Q2 2025 vs Q1 2025; Q4 2025 expansion to new mark
Slide 5: Harrow’s Portfolio of Ophthalmic Pharmaceutical Brands
Harrow’s Portfolio of Ophthalmic Pharmaceutical Brands Investor Presentation | August 2025 5
Slide 6: Harrow's Three Commercial Channels
Harrow's Three Commercial Channels SPECIALTY PRESCRIPTION BUY & BILL COMPOUNDED One of the largest portfolios Best-in-class products Leading U.S. ophthalmic of branded ophthalmology compounding business products in U.S. America’s #1 trusted resource for ophthalmic compounded medications 6 Investor P
Slide 7: Q2 2025 Key Financial Metrics
Q2 2025 Key Financial Metrics (in thousands) Consolidated Revenues Adjusted EBITDA ‘25 Guidance > $280,000 $40,327 $199,614 $28,119 $17,006 Adjusted EBITDA in Q2 2025 $130,193 $15,021 $88,595 $13,017 $11,378 $63,743 $72,476 Q2 25 $111,574 $48,871 H1 25 $5,715 $47,831 Q1 25 20 21 22 23 24 25 20 21 22
Slide 8: Q2 2025 Key Growth Drivers
Q2 2025 Key Growth Drivers Specialty Branded Q1 2025 Revenue $21.5M $5.2M $1.0M $20.5M Q2 2025 Revenue $18.6M $18.3M $5.2M $21.5M H1 25 $X Expected H2 2025 $60M+ $27M+ $44M+ $39M+ Revenue 2025 Guidance $100M+ $50M+ $50M+ $80M+ (1) Adjusted EBITDA is defined as net income (loss), excluding the effect
Slide 9: Specialty Products (Branded)
Specialty Products (Branded) 9 Investor Presentation | August 2025
Slide 10: VEVYE – A Best-in-Class Solution for Dry Eye Disease
VEVYE – A Best-in-Class Solution for Dry Eye Disease DED Patient Population The first and only water-free cyclosporine to treat Dry Eye prevalence is continuing to grow with aging the signs and symptoms of dry eye disease populations, increased screen time and poor diets • In a pre-clinical ex-vivo
Slide 11: VEVYE Access For All (VAFA)
VEVYE Access For All (VAFA) Eyecare professional Specialty pharmacy Patient receives VEVYE regardless of prescribes VEVYE through dispenses VEVYE insurance coverage for $0-$59 per bottle1-3* specialty pharmacy • Remove Barriers to Access for Patients and Providers • No prior authorization submission
Slide 12: VEVYE Q2 2025 Key Metrics
VEVYE Q2 2025 Key Metrics VEVYE Quarterly Prescriptions (January 2024 launch) • Q2 TRx up 66% & NRx volume up 62% post (Based on Internal Data)(1) launch of VAFA, with a significant increase in the number of HCPs writing directly to PhilRx 119,526 • High refill rates with the average covered The com
Slide 13: VEVYE Q2 2025 Market Share
VEVYE Q2 2025 Market Share Market Share as of Q2 2025* • As of Q2 2025, VEVYE has captured 7.8% of 7.80% the total DED market, an increase of 2.6% 2.6% Growth from Q1 2025 Q1-25 vs. Q2-25 • Harrow’s primary strategic goal is – to become the number one most prescribed cyclosporine 5.20% • In Q1 2025,
Slide 14: Anterior Segment Products
Anterior Segment Products “Workhorse” products in U.S. optometry and ophthalmology offices OTC Preservative-Free Antihistamine, Antibiotics, and Steroids, NSAIDs, and Anti-inflammatories Lubricant Antibiotic + Steroid Combination The only FDA-approved Prescription Product for The only FDA-approved G
Slide 15: BYQLOVI – Best-in-Class Steroid
BYQLOVI – Best-in-Class Steroid A recent acquisition leveraging Harrow’s commercial infrastructure Description: • BYQLOVI is an FDA-approved steroid to treat inflammation and pain after ocular surgery • Super potent and unique steroid: BYQLOVI is the only FDA-approved ocular steroid that utilizes cl
Slide 16: Buy & Bill Products
Buy & Bill Products (Anesthetics, Therapeutics) 16 Investor Presentation | August 2025
Slide 17: Recent Launch of Harrow Cares HUB
Recent Launch of Harrow Cares HUB • Partnered with Cencora for reimbursement support through Harrow Cares HUB for IHEEZO and TRIESENCE • Provides customer with reimbursement confidence and support • Patient benefits verification and investigation • Commercial patient co-pay support • Provides up to
Slide 18: IHEEZO Overview
IHEEZO Overview • First approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride • First branded ocular anesthetic approved for the U.S. market in nearly 14 years Sterile, single-patient-use, • IHEEZO Reimbursement: physician-administered, ophthalmic gel preparation • Permanent J-C
Slide 19: IHEEZO Q2 2025 Key Metrics
IHEEZO Q2 2025 Key Metrics IHEEZO Quarterly Customer Unit Demand(1) • "Retina Pivot" re-focused (May 2023 launch) commercial efforts on retina specialist community for use in Q1 seasonality intravitreal injection market. typical for OPH buy 49,130 and bill products 48,765 • Agreements with all 4 maj
Slide 20: TRIESENCE
TRIESENCE Description:(1) • The only FDA-approved preservative-free synthetic corticosteroid with separate reimbursement in all traditional settings of care Q2 2025 Highlights: Supply Chain: • 870 new accounts YTD • Five-year supply agreement with current CMO • Next-generation product development un
Slide 21: Best-in-Class anti-VEGF Biosimilars
Best-in-Class anti-VEGF Biosimilars Recently entered into an agreement with Samsung Bioepis to acquire U.S. commercials rights to portfolio of ophthalmic biosimilars, including BYOOVIZ (Lucentis) and OPUVIZ (Eylea) BYOOVIZ (ranibizumab-nuna) 0.05mL injection, the OPUVIZ (aflibercept-yszy) 0.05mL inj
Slide 22: U.S. Ophthalmic Market Share-Anti-VEGF’s
U.S. Ophthalmic Market Share-Anti-VEGF’s ~8.5M Units Across All Products Unit Volume1 BYOOVIZ (Lucentis) & OPUVIZ (Eylea) offers 2,550,000 2,550,000 a compelling value proposition and cost- effective alternative to current Anti-VEGF therapies & compounded Avastin: 191 M 1,445,000 • Clinically valida
Slide 23: Compounded Products
Compounded Products 23 Investor Presentation | August 2025
Slide 24: ImprimisRx
ImprimisRx Revenues* • Leading U.S. ophthalmic-focused (Dollars in thousands) compounding business • More than 15,000 U.S. customers $83,499 $82,013 $79,935 • 50-state dispensing capabilities $69,104 • Broad therapeutic product portfolio $48,475 $41,519 • Strategies underway to improve gross margins
Slide 25: Equity Ownership – Melt Pharmaceuticals
Equity Ownership – Melt Pharmaceuticals • Melt Pharmaceuticals is a former subsidiary of Harrow 0% 0% • MELT-300 is a non-IV and non-opioid sublingual sedation drug candidate for short-duration medical procedures • MELT-300 is patented in the U.S. and key global markets Harrow 46% • Potential impact
Slide 26: > 59 prescription products
Harrow – A Leading Provider of Ophthalmic Disease Management Solutions in North America Largest U.S. portfolio of ophthalmic Key revenue drivers are best-in- Scalable commercial platform prescription products for the front & class products with large market with an innovative market back of the eye
Slide 27: Commitment to Supporting Mission Trips
Commitment to Supporting Mission Trips See Intl Eye Doctors of Lancaster Nevis Eye Care Health in Sight Missions (Honduras) April 2024 (Africa) October 2024 (West Indies) November 2024 (Honduras) February 2025 During 2024, Harrow’s donations helped approximately 17,000 To date, in 2025, Harrow has c
Slide 28: Mike Biega
1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 Harrow.com Mike Biega Vice President of Investor Relations & Communications mbiega@harrowinc.com Direct: 617-913-8890 28 Investor Presentation | August 2025